Company
Salix
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
17
9 still marketed
Novel approvals
3
Approvals since 2021
0
Originals and new uses
Phase 3 trials
0
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Trulance new use Jan 24, 2018
- Trulance approved NovelJan 19, 2017
- Relistor approved Jul 19, 2016
- Xifaxan new use Priority reviewMay 27, 2015
- Uceris approved Oct 7, 2014
- Relistor new use Sep 29, 2014
- Uceris approved Jan 14, 2013
- Xifaxan approved Priority reviewOrphanMar 24, 2010
- Metozolv Odt approved Sep 4, 2009
- Apriso approved Oct 31, 2008
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (9)
Newest FDA action first.
- Apriso Mesalamine · 2008
- Uceris Budesonide · 2013
- Xifaxan Rifaximin · 2004
- Moviprep Ascorbic Acid, Polyethylene Glycol 3350, Potassium Chloride, Sodium Ascorbate, Sodium Chloride, Sodium Sulfate · 2006
- Trulance Plecanatide · 2017
- Uceris Budesonide · 2014
- Relistor Methylnaltrexone Bromide · 2008
- Relistor Methylnaltrexone Bromide · 2016
- Xifaxan Rifaximin · 2010
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.